| SSOAIC used as first line therapy for unilateral disease group E |
0/14 |
2/7 (28.6) |
0.1 |
| SSOAIC used as first line therapy for unilateral disease group D |
8/14 (57.1) |
7/7 (100) |
0.05 |
| SSOAIC used as first line therapy for unilateral disease groups B and C |
6/14 (42.9) |
7/7 (100) |
0.01 |
| SSOAIC used as first line therapy for bilateral disease group D |
2/14 (14.3) |
5/7 (71.4) |
0.01 |
| SSOAIC used as first line therapy for bilateral disease groups B and C |
1/14 (7.1) |
5/7 (71.4) |
0.01 |
| SSOAIC used as second line therapy for uni or bilateral disease before considering EBRT |
7/14 (50) |
6/7 (85.7) |
0.17 |
| SSOAIC used as second line therapy for bilateral disease in eyes that received EBRT |
3/14 (21.4) |
6/7 (85.7) |
0.15 |
| Use of single agent melphalan as only therapy |
7/12 (58.3) |
4/7 (57.1) |
1 |
| Perception that SSOAIC improve the results in conservative therapy |
8/12 (66.7) |
7/7 (100) |
0.24 |
